75N95024F00001

REGULATORY CONSULTING ASSISTANCE FOR MEDICAL DEVICE DEVELOPER. RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. PRE-SUBMISSION ASSESSMENT & PACKAGE PREPARATION. TASK ORDER 03. 04/09/2024 - 04/08/2029.

Research the contractor View USAspending source Save to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

Field	Reported value
Agency	Department of Health and Human Services
Office	NATIONAL INSTITUTES OF HEALTH NIDA
NAICS	541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC	AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Parent award / vehicle	75N95022D00020
Set-aside	Not reported
Pricing type	COST PLUS FIXED FEE
Obligations	$370.6K
Current contract value	$370.6K
Potential contract value / ceiling	$370.6K
Start date	Apr 9, 2024
Current end date	Apr 8, 2029
Potential end date	Apr 8, 2029
Latest award activity	Mar 13, 2025
Source loaded	Sep 26, 2026

Funding and modification history

Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.

Date	Modification	Obligation change	Description
Mar 13, 2025	P00005	$181.8K	CONTRACT RESEARCH ORGANIZATION (CRO) SUPPORT FOR BLUEPRINT MEDTECH (BPMT) REGULATORY AFFAIRS SUPPORT AND RELATED SERVICES. REGULATORY PATHWAY AND MARKET ACCESS SUPPORT. TASK ORDER 03. 04/09/2024 - 04/08/2029.
Dec 5, 2024	P00004	$3.5K	CONTRACT RESEARCH ORGANIZATION (CRO) SUPPORT FOR BLUEPRINT MEDTECH (BPMT) REGULATORY AFFAIRS SUPPORT AND RELATED SERVICES. REGULATORY PATHWAY AND MARKET ACCESS SUPPORT. TASK ORDER 03. 04/09/2024 - 04/08/2029.
Aug 13, 2024	P00003	$169.6K	CONTRACT RESEARCH ORGANIZATION (CRO) SUPPORT FOR BLUEPRINT MEDTECH (BPMT) REGULATORY AFFAIRS SUPPORT AND RELATED SERVICES. REGULATORY PATHWAY AND MARKET ACCESS SUPPORT. TASK ORDER 03. 04/09/2024 - 04/08/2029.
Jul 12, 2024	P00002	$1.7K	CONTRACT RESEARCH ORGANIZATION (CRO) SUPPORT FOR BLUEPRINT MEDTECH (BPMT) REGULATORY AFFAIRS SUPPORT AND RELATED SERVICES. REGULATORY PATHWAY AND MARKET ACCESS SUPPORT. TASK ORDER 03. 04/09/2024 - 04/08/2029.
May 6, 2024	P00001	$12.2K	REGULATORY CONSULTING ASSISTANCE FOR MEDICAL DEVICE DEVELOPER. RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. PRE-SUBMISSION ASSESSMENT & PACKAGE PREPARATION. TASK ORDER 03. 04/09/2024 - 04/08/2029.
Apr 9, 2024	0	$1.7K	REGULATORY CONSULTING ASSISTANCE FOR MEDICAL DEVICE DEVELOPER. RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. PRE-SUBMISSION ASSESSMENT & PACKAGE PREPARATION. TASK ORDER 03. 04/09/2024 - 04/08/2029.

Estimated positioning window

Apr 8, 2028 – Oct 8, 2028

Recompete signal:

60/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 60/100. Available recorded signals: 55 points.

Contract end 2029-04-08 (896 days from calculation): +15 points
173 historical awards in this buyer and category group: +15 points
6 recorded award transactions: +10 points
Latest award action: 2025-03-13: +0 points
Parent award identifier recorded: +5 points
Solicitation identifier recorded: +10 points
Linked official forecast: +0 points
Calculated on: 2026-10-25 10:18:04.631876+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Oct 25, 2026.

Research next steps

Check the linked forecast or SAM for a confirmed solicitation and current timing.
Confirm the ordering vehicle and your eligibility or a qualified teaming route.
Review the award scope and buyer evidence before making a bid/no-bid decision.